StockData
Vivos Therapeutics, Inc. logo

Vivos Therapeutics, Inc. (VVOS) stock

VVOSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 3/30
$0.10+0.00 (+2.40%)

Close on Nov 13, 2026Market cap $1.97MP/E –Yield –

Vivos Therapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Vivos Therapeutics's profit margin for the twelve months ending Jun 30, 2026 was -121.8%. For fiscal 2025 it was -121.4%, against -74.1% the year before. The highest annual figure on record is -74.1% in fiscal 2024.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-121.4%−47.3
FY2024Dec 31, 2024-74.1%+24.3
FY2023Dec 31, 2023-98.4%+50.4
FY2022Dec 31, 2022-148.8%−28.7
FY2021Dec 31, 2021-120.2%−27.9
FY2020Dec 31, 2020-92.3%+2.1
FY2019Dec 31, 2019-94.4%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-106.4%+24.9
Q1 FY2026Mar 31, 2026-149.4%−21.3
Q4 FY2025Dec 31, 2025-180.3%−103.8
Q3 FY2025Sep 30, 2025-79.6%−11.8
Q2 FY2025Jun 30, 2025-131.2%−83.6
Q1 FY2025Mar 31, 2025-128.1%−18.1
Q4 FY2024Dec 31, 2024-76.4%+54.7
Q3 FY2024Sep 30, 2024-67.8%−4.4
Q2 FY2024Jun 30, 2024-47.6%+115.2
Q1 FY2024Mar 31, 2024-110.1%−65.9
Q4 FY2023Dec 31, 2023-131.1%+23.0
Q3 FY2023Sep 30, 2023-63.4%+64.6
Q2 FY2023Jun 30, 2023-162.8%+4.3
Q1 FY2023Mar 31, 2023-44.2%+102.1
Q4 FY2022Dec 31, 2022-154.2%+14.1
Q3 FY2022Sep 30, 2022-128.0%−8.0
Q2 FY2022Jun 30, 2022-167.1%−77.2
Q1 FY2022Mar 31, 2022-146.3%−47.7
Q4 FY2021Dec 31, 2021-168.3%+20.7
Q3 FY2021Sep 30, 2021-120.0%−64.9
Q2 FY2021Jun 30, 2021-89.9%−46.7
Q1 FY2021Mar 31, 2021-98.6%−17.8
Q4 FY2020Dec 31, 2020-189.0%–
Q3 FY2020Sep 30, 2020-55.1%–
Q2 FY2020Jun 30, 2020-43.2%–
Q1 FY2020Mar 31, 2020-80.7%–

More Vivos Therapeutics figures

See a number that looks wrong?